Explore the vast range of titles available.

\"Examines patterns of income inequality among 16 advanced democracies from the mid 1970s to the early 2000s and explains why some societies have a large and growing divide between the rich and the poor while others, facing similar global economic pressures, maintain more egalitarian income distributions\"--Provided by publisher.

Labour market institutions, including collective bargaining, the regulation of employment contracts and social protection policies, are instrumental for improving the well-being of workers, their families and society. In many countries, these institutions have been eroded, whilst in other countries they do not exist at all.

Reliable information on how health service strategies affect the poor is in short supply. In an attempt to redress the imbalance, 'Improving Health Service Delivery in Developing Countries' presents evidence on strategies for strengthening health service delivery, based on systematic reviews of the literature, quantitative and qualitative analyses of existing data, and seven country case studies. The authors also explore how changes in coverage of different health services affect each other on the national level. Finally, the authors explain why setting international targets for health services has been not been successful and offer an alternative approach based on a specific country's experience. The book's findings are clear and hopeful: There are many ways to improve health services. Measuring change and using information to guide decisions and inform stakeholders are critically important for successful implementation. Asking difficult questions, using information intelligently, and involving key stakeholders and institutions are central to the \"learning and doing\" practices that underlie successful health service delivery.

Microbiology of Drinking Water Production and Distribution addresses the public health aspects of drinking water treatment and distribution. It explains the different water treatment processes, such as pretreatment, coagulation, flocculation, sedimentation, filtration, disinfection, and their impacts on waterborne microbial pathogens and parasites. Drinking water quality may be degraded in water distribution systems—microorganisms form biofilms within distribution systems that allow them to flourish. Various methodologies have been proposed to assess the bacterial growth potential in water distribution systems. Microbiology of Drinking Water Production and Distribution also places drinking water quality and public health issues in context; it addresses the effect of bioterrorism on drinking water safety, particularly safeguards that are in place to protect consumers against the microbial agents involved. In addition, the text delves into research on drinking water quality in developing countries and the low-cost treatment technologies that could save lives. The text also examines the microbiological water quality of bottled water, often misunderstood by the public at large.

Traditional pathways to delivering health care to the global poor are failing. Five million children die each year before their fifth birthday due to lack of basic health education, services, or low-cost treatments. Bing and Epstein show how focusing micro-innovations at the level of care is the way to end these grim health statistics.

The revised and updated second edition of Water and Sanitation Related Diseases and the Changing Environment offers an interdisciplinary guide to the conditions responsible for water and sanitation related diseases. The authors discuss the pathogens, vectors, and their biology, morbidity and mortality that result from a lack of safe water and sanitation. The text also explores the distribution of these diseases and the conditions that must be met to reduce or eradicate them. The text includes contributions from authorities from the fields of climate change, epidemiology, environmental health, environmental engineering, global health, medicine, medical anthropology, nutrition, population, and public health. Covers the causes of individual diseases with basic information about the diseases and data on the distribution, prevalence, and incidence as well as interconnected factors such as environmental factors. The authors cover access to and maintenance of clean water, and guidelines for the safe use of wastewater, excreta, and grey water, plus examples of solutions. Written for students, and professionals in infectious disease, public health and medicine, chemical and environmental engineering, and international affairs, the second edition of Water and Sanitation Related Diseases and the Changing Environment isa comprehensive resource to the conditions responsible for water and sanitation related diseases.

This study aims to determine whether the effect of income inequality on economic growth is realised through transmission channels theoretically expressed. This relationship is examined for 143 countries and the periods between 1980 and 2017 through positive and negative channels. These countries are divided into two groups by considering their income levels and they are analysed with panel data econometric techniques. Although the findings provide evidence that high inequality adversely affects economic growth, it can be stated that this inference cannot be generalized when countries' income levels are taken into account. Countries with higher inequality tend to have higher fertility rates and less innovative activity. The financial market imperfections in developing countries adversely affect human capital investments. On the other hand, high inequality tends to increase saving propensity in developed countries and provides evidence for the positive channel. The findings highlight the complexity of the impact of income inequality on economic growth. Therefore, indirect impact needs to be scrutinized and policy recommendations need to be carefully designed.

Antihypertensive medicines are effective in reducing adverse cardiovascular events. Our aim was to compare hypertension awareness, treatment, and control, and how they have changed over time, in high-income countries. We used data from people aged 40–79 years who participated in 123 national health examination surveys from 1976 to 2017 in 12 high-income countries: Australia, Canada, Finland, Germany, Ireland, Italy, Japan, New Zealand, South Korea, Spain, the UK, and the USA. We calculated the proportion of participants with hypertension, which was defined as systolic blood pressure of 140 mm Hg or more, or diastolic blood pressure of 90 mm Hg or more, or being on pharmacological treatment for hypertension, who were aware of their condition, who were treated, and whose hypertension was controlled (ie, lower than 140/90 mm Hg). Data from 526 336 participants were used in these analyses. In their most recent surveys, Canada, South Korea, Australia, and the UK had the lowest prevalence of hypertension, and Finland the highest. In the 1980s and early 1990s, treatment rates were at most 40% and control rates were less than 25% in most countries and age and sex groups. Over the time period assessed, hypertension awareness and treatment increased and control rate improved in all 12 countries, with South Korea and Germany experiencing the largest improvements. Most of the observed increase occurred in the 1990s and early-mid 2000s, having plateaued since in most countries. In their most recent surveys, Canada, Germany, South Korea, and the USA had the highest rates of awareness, treatment, and control, whereas Finland, Ireland, Japan, and Spain had the lowest. Even in the best performing countries, treatment coverage was at most 80% and control rates were less than 70%. Hypertension awareness, treatment, and control have improved substantially in high-income countries since the 1980s and 1990s. However, control rates have plateaued in the past decade, at levels lower than those in high-quality hypertension programmes. There is substantial variation across countries in the rates of hypertension awareness, treatment, and control. Wellcome Trust and WHO.

WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability. We analysed information about availability and costs of cardiovascular disease medicines (aspirin, β blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries participating in the Prospective Urban Rural Epidemiology (PURE) study. Medicines were considered available if present at the pharmacy when surveyed, and affordable if their combined cost was less than 20% of household capacity-to-pay. We compared results from high-income, upper middle-income, lower middle-income, and low-income countries. Data from India were presented separately given its large, generic pharmaceutical industry. Communities were recruited between Jan 1, 2003, and Dec 31, 2013. All four cardiovascular disease medicines were available in 61 (95%) of 64 urban and 27 (90%) of 30 rural communities in high-income countries, 53 (80%) of 66 urban and 43 (73%) of 59 rural communities in upper middle-income countries, 69 (62%) of 111 urban and 42 (37%) of 114 rural communities in lower middle-income countries, eight (25%) of 32 urban and one (3%) of 30 rural communities in low-income countries (excluding India), and 34 (89%) of 38 urban and 42 (81%) of 52 rural communities in India. The four cardiovascular disease medicines were potentially unaffordable for 0·14% of households in high-income countries (14 of 9934 households), 25% of upper middle-income countries (6299 of 24 776), 33% of lower middle-income countries (13 253 of 40 023), 60% of low-income countries (excluding India; 1976 of 3312), and 59% households in India (9939 of 16 874). In low-income and middle-income countries, patients with previous cardiovascular disease were less likely to use all four medicines if fewer than four were available (odds ratio [OR] 0·16, 95% CI 0·04–0·57). In communities in which all four medicines were available, patients were less likely to use medicines if the household potentially could not afford them (0·16, 0·04–0·55). Secondary prevention medicines are unavailable and unaffordable for a large proportion of communities and households in upper middle-income, lower middle-income, and low-income countries, which have very low use of these medicines. Improvements to the availability and affordability of key medicines is likely to enhance their use and help towards achieving WHO's targets of 50% use of key medicines by 2025. Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or local organisations in participating countries.

Market Menagerie examines technological advance and market regulation in the health industries of nations such as India, Brazil, South Africa, Nigeria, and Japan. Pharmaceutical and life science industries can reinforce economic development and industry growth, but not necessarily positive health outcomes. Yet well-crafted industrial and health policies can strengthen each other and reconcile economic and social goals. This book advocates moving beyond traditional market failure to bring together three uncommonly paired themes: the growth of industrial capabilities, the politics of health access, and the geography of production and redistribution.